EDISYN was founded to serve a unique population of patients, those with inherited predisposition to cancer, with the goal of advancing techniques of cancer surveillance through scientific exploration. Together, physician-scientists, clinicians, laboratory specialists, genetic counselors, and research coordinators all play unique roles within the organization. In addition, we have partnered closely with leaders of patient advocacy groups strengthening our connection with the community.
EDISYN brings together physician-scientists who have focused clinical and research interest in improving outcomes for patients with Li-Fraumeni Syndrome and other cancer predisposition syndromes. We are partnering with patients who have generously agreed, through participation in research and banking studies, to contribute data and blood samples to develop novel non-invasive liquid biopsy tests that can detect the presence of cancer before it is otherwise detectable.